Clinical Trials Browser

Phase 2 × Recruiting × NETWORK × Clear all

NCT07107529 2026-04-15

Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.

Phase 2 Recruiting

Multiple Myeloma

NCT05640999 2026-04-14

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

Phase 2 Recruiting

Endometrial Neoplasms

NCT05998642 2026-04-14

Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

Phase 2 Recruiting

Lymphoma, Non-Hodgkin

NCT06880523 2026-04-14

SLIDE-HCC

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT05289687 2026-04-03

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06319027 2026-04-03

GABLE

Phase 2 Recruiting

Glioblastoma

NCT07328425 2026-04-03

ISG-TULIPS

Phase 2 Recruiting

Desmoplastic Small Round Cell Tumor

NCT06368414 2026-04-02

AsterA

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase

NCT06368817 2026-03-31

A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

Phase 2 Recruiting

Diabetes Insipidus, Germinoma

NCT06769126 2026-03-30

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Phase 2 Recruiting

Small Cell Lung Carcinoma

NCT03297606 2026-03-27

CAPTUR

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT04305548 2026-03-27

ISG-MCS

Phase 2 Recruiting

Chondrosarcoma, Mesenchymal

NCT05601440 2026-03-27

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT06623461 2026-03-27

Canbiome2

Phase 2 Recruiting

Melanoma

NCT04383119 2026-03-25

ISG-ARTICLE

Phase 2 Recruiting

Sarcoma

NCT02734537 2026-03-23

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

Phase 2 Recruiting

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

NCT03493425 2026-03-23

Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery

Phase 2 Recruiting

Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7

NCT06859424 2026-03-17

ACCELERATE

Phase 2 Recruiting

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Lymphoma, Myeloproliferative Disorders, Leukemia, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT04305691 2026-02-27

Trial of Ixazomib for Kaposi Sarcoma

Phase 2 Recruiting

Sarcoma, Kaposi

NCT06410209 2026-02-27

A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study

Phase 2 Recruiting

Other solid neoplasm

Hematopoietic and Lymphatic System Neoplasm

NCT04322318 2026-02-24

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

Phase 2 Recruiting

Wilms Tumor

NCT04684368 2026-02-24

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

Phase 2 Recruiting

Choriocarcinoma, Teratoma, Carcinoma, Embryonal

NCT02981628 2026-02-23

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Phase 2 Recruiting

80 enrolled 1 FDA

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT06219317 2026-02-23

ICARS

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05504291 2026-02-17

A Study to Give Treatment Inside the Eye to Treat Retinoblastoma

Phase 2 Recruiting

Other solid neoplasm

Retinoblastoma

NCT04918186 2026-02-12

IPROC

Phase 2 Recruiting

Ovarian Neoplasms

NCT05718323 2026-02-06

RAISE

Phase 2 Recruiting

SCLC,Extensive Stage

NCT05180097 2026-02-02

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Phase 2 Recruiting

Hodgkin Disease

NCT05633615 2026-02-02

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT05806515 2026-01-29

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

Phase 2 Recruiting

Prostatic Neoplasms

NCT06031688 2026-01-23

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05040360 2025-12-15

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

Phase 2 Recruiting

Adenoma, Islet Cell

NCT05642572 2025-12-05

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06116682 2025-12-05

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04205968 2025-11-05

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

Phase 2 Recruiting

Metastatic Small Intestinal Adenocarcinoma

NCT05890352 2025-10-20

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT07209059 2025-10-06

FINISH-HL

Phase 2 Recruiting

Hodgkin Disease

NCT06649695 2025-09-25

A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis

Phase 2 Recruiting

Immunoglobulin Light-chain Amyloidosis

NCT05694936 2025-09-18

Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06326190 2025-09-16

LUMEN-1

Phase 2 Recruiting

Meningioma

NCT04511013 2025-09-11

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

Phase 2 Recruiting

CNSDermatologic

Brain Neoplasms, Melanoma

NCT01766297 2025-09-09

Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT02598349 2025-09-09

Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas

Phase 2 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT07130032 2025-08-19

reICB

Phase 2 Recruiting

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT06345079 2025-08-14

STOPNET

Phase 2 Recruiting

Neuroendocrine Tumors

NCT06441747 2025-07-29

Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

Phase 2 Recruiting

Gastrointestinal

Cholangiocarcinoma

NCT06290505 2025-07-23

PALEO

Phase 2 Recruiting

Gastrointestinal

Esophageal Neoplasms

NCT06171685 2025-07-15

MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM

Phase 2 Recruiting

Multiple Myeloma

NCT03847649 2025-06-11

A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies

Phase 2 Recruiting

Neoplasms

NCT04375904 2025-05-02

SOURCE Lung

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms